Cantor Fitzgerald Predicts VRTX FY2026 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould forecasts that the pharmaceutical company will post earnings of $18.36 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $535.00 target price on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Several other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. boosted their price target on Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an “overweight” rating in a research report on Tuesday, May 6th. The Goldman Sachs Group reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Bank of America increased their price target on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Wall Street Zen upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 11th. Finally, Erste Group Bank downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 23rd. Fourteen analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $515.04.

Vertex Pharmaceuticals Trading Up 1.7%

NASDAQ VRTX opened at $460.06 on Wednesday. The firm’s fifty day moving average is $462.88 and its two-hundred day moving average is $460.24. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The firm has a market cap of $118.14 billion, a PE ratio of -209.12, a P/E/G ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $4.76 EPS.

Institutional Trading of Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Activest Wealth Management acquired a new position in shares of Vertex Pharmaceuticals in the first quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth $31,000. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth $32,000. Finally, Golden State Wealth Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $37,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.